38411-85-7

Taurohyodeoxycholic acid sodium is the taurine-conjugated form of the secondary bile acid hyodeoxycholic acid. 1 THDCA reduces the size and weight of human gallstones in vitro. It increases bile flow, bile cholesterol secretion and bile lipid secretion in rats. 2 Co-administration of THDCA and taurochenodeoxycholic acid prevented TCDCA-induced hepatotoxicity and increased bile flow and bile acid and phospholipid secretion in rats. 3 THDCA can also reduce the activity and expression of myeloperoxidase TNF-α and IL-6, as well as colonic damage in TNBS-induced ulcerative colitis mouse model. 41. Angelico, M., Mogavero, L., Baiocchi, L., et al. Dissolution of human cholesterol bile salts/lecithin mixtures for gallstones: effects of bile salt hydrophobicity and various pHsScand. J. Gastroenterol.30(12)1178-1185(1995) 2.Angelico, M., Baiocchi, L., Nistri, A., et al.Effect of taurohodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid 2. Angelico, M., Baiocchi, L., Nistri, A., et al. Effect of taurohyodeoxycholic acid, a hydrophilic bile salt, on bile salt and biliary lipid secretions in rats. Sci.39(11)2389-2397(1994) 3.Roda, A., Piazza, F., Baraldini, M., et al.Taurohyodeoxycholic acid protects against taurochenodeoxycholic acid-induced cholestasis in the rataHepatology27(2)520-525 (1998) 4.He, J., Liang, J., Zhu, S., et al. Protective effect of pig powder taurine hyodeoxycholic acid on trinitrobenzenesulfonic acid-induced ulcerative colitis in mice Eur . J. Pharmacol. 670(1) 229-235(2011)